Acute Pancreatitis (AP) Market Insights, Trends, Epidemiology, and Forecast to 2030 for United States, Germany, Spain, Italy, France, United Kingdom, and Japan – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Acute Pancreatitis (AP) – Market Insights, Epidemiology, and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report delivers an in-depth understanding of the Acute Pancreatitis (AP), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted AP symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current Acute Pancreatitis (AP) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Study Period: 2017-2030

Epidemiology

The epidemiology division’s Acute Pancreatitis symptoms provides insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Acute Pancreatitis (AP) epidemiology segmented as the Diagnosed Incident Cases of Acute Pancreatitis (AP), Gender-specific cases of Acute Pancreatitis (AP), Diagnosed Incident Cases of Acute Pancreatitis (AP) by Etiology and Diagnosed Incident Cases of Acute Pancreatitis (AP) by Severity. The report includes the Incident scenario of AP symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise Epidemiology

The epidemiology segment also provides the Acute Pancreatitis (AP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total 7MM incident cases of Acute Pancreatitis (AP) were 502,390 in 2020.

Drug Chapters

The drug chapter segment of the Acute Pancreatitis (AP) report encloses the detailed analysis of AP drugs. It also helps understand the Acute Pancreatitis (AP) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs

CalciMedica’s lead product candidate, Auxora (formerly CM4620), a proprietary intravenous-formulated CRAC channel inhibitor, is being developed for several indications including the treatment of acute inflammatory diseases associated with dysregulation of intracellular calcium in organ tissues like the lung, pancreas or kidneys such as that of Acute Pancreatitis (AP).

Market Outlook

The Acute Pancreatitis (AP) market outlook of the report helps build the detailed comprehension of the historic, current and forecasted Acute Pancreatitis (AP) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Acute Pancreatitis (AP) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Key Findings

This section includes a glimpse of the Acute Pancreatitis (AP) market in 7MM. The market size of AP in the seven major markets was found to be USD 710.61 million in 2020 and market is estimated to increase at a CAGR of 5.89% for the study period (2017-2030).

The United States Market Outlook

This section provides a total of Acute Pancreatitis (AP) market size and market size by therapies in the United States.

The United States accounts for the highest AP market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Acute pancreatitis is one of the most frequent gastrointestinal cause of hospital admissions in the US where patients typically present with severe, continuous upper abdominal pain radiating to the back. There are several factors which have led to an increase in the incidence of AP such as increasing incidence of obesity which promotes gallstone formation along with the increased availability of and use of tests to measure serum levels of pancreatic enzymes, which detect milder cases of AP.

Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Acute Pancreatitis (AP) market uptake by drugs; patient uptake by therapies; and drug sales.

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Pipeline Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Acute Pancreatitis (AP) key players involved in developing targeted therapeutics.

Major players include Auxora (CalciMedica) being assessed as potential therapies to be available in the market in the coming future.

Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Acute Pancreatitis (AP) emerging therapies.

Reimbursement Scenario

While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient’s claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do his or her best to make sure that the patient receives Social Security Disability benefits as quickly as possible and will help the patient avoid the lengthy disability appeal process

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Acute Pancreatitis (AP) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or the Acute Pancreatitis (AP) market trend. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive & Market Intelligence analysis of the Acute Pancreatitis (AP) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Acute Pancreatitis (AP), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
• Comprehensive insight has been provided into the Acute Pancreatitis (AP) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Acute Pancreatitis (AP) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Acute Pancreatitis (AP) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute Pancreatitis (AP) market

Key Topics Covered

1 Key Insights

2 Executive Summary for Acute Pancreatitis

3 SWOT Analysis for Acute Pancreatitis

4 Acute pancreatitis Market Overview at a Glance

4.1 Market Share (%) Distribution of AP in 2017

4.2 Market Share (%) Distribution of AP in 2030

5 Disease Background and Overview

5.1 Introduction

5.2 Classification

5.3 Causes

5.4 Symptoms and Complications

5.5 Pathophysiology

5.6 Diagnosis

5.7 Biomarkers

6 Epidemiology and Patient Population

6.1 Key Findings

7 Total Diagnosed Incident Population of Acute Pancreatitis

8 Country Wise-Epidemiology of Acute Pancreatitis

8.1 The United States

8.2 EU5 Countries

8.3 Japan

9 Treatment and Management of Acute Pancreatitis

9.1 Japanese guidelines for the management of acute pancreatitis

9.2 American guidelines for the management of acute pancreatitis

9.3 Treatment Goals

9.4 Patient Journey for Acute Pancreatitis

10 Unmet Needs

11 Emerging Therapies

11.1 Auxora: CalciMedica, Inc.

11.1.1 Product Description

11.1.2 Other development activities

11.1.3 Clinical Development

11.1.3.1 Clinical Trials Information

12 Acute Pancreatitis: 7 Major Market Analysis

12.1 Key Findings

12.2 Total Market Size of Acute Pancreatitis in 7MM

13 Market Outlook by Country

13.1 Market Outlook

13.2 United States Market Size

13.3 EU-5

13.4 Japan: Market Outlook

14 Market Drivers

15 Market Barriers

16 Market Access and Reimbursement

16.1 Access to Medicines for Acute Pancreatitis in US

16.2 Access to Medicines for Acute Pancreatitis in Europe

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/p6g71s

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900